Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis
The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Abstract
Newer atypical antipsychotic drugs such as risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole that have been modelled on the prototype agent clozapine and developed since the 1990 s are now referred to as second-generation antipsychotic drugs (SGAs). It has been proposed that the interaction between serotonin (5-HT) and dopamine systems may play a critical role in the mechanism of action of atypical antipsychotic drugs because a relatively potent blockade of 5-HT(2A) receptors coupled with the weaker antagonism of the dopamine D(2) receptors is found to be the only pharmacological feature which most atypical antipsychotic drugs have in common. This so-called 'serotonin-dopamine hypothesis' has become a useful model for developing new SGAs to achieve superior antipsychotic efficacy with a lower incidence of extrapyramidal side effects compared to those with first-generation antipsychotic drugs (FGAs) such as haloperidol and chlorpromazine, although it has not been validated yet. In contrast, it has been proposed as the alternative 'fast-off' theory according to which atypical profile of SGAs can be determined by the loose D(2)-binding kinetics alone, while the blockade of the 5-HT(2A) receptor may be neither necessary nor sufficient. This chapter reviews the current issues on the serotonin-dopamine hypothesis together with further advances in research on the role of 5-HT receptor subtypes in the mechanism of action for SGAs. In particular, SGA-induced dopamine release in the prefrontal cortex, possibly through the functional activation of 5-HT(1A) receptors by 5-HT(2A) and D(2) receptor-mediated interaction, has been thought to be the basis for the neurocognitive effects of these drugs on schizophrenia. Thus, the novel antipsychotic aripiprazole may not only be a simply partial D(2) agonist but also a significant 5-HT(1A) agonist and 5-HT(2A) antagonist. These complex properties of antipsychotic aripiprazole may contribute to dopaminergic activation of the local circuitry in the prefrontal cortex of schizophrenic patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, quetiapine, but not olanzapine, may increase DA levels [39], preferentially in the NAc shell [40], with some data [41] suggesting as well a quetiapine-associated enhancement of cocaine reinforcing potency.”
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062 · cited 1×
“Proposal of the theory corresponded to the same time that some clinical studies began to suggest comparative effects of SGAs versus low-dose or low-potent FGAs with regard to clinical efficacy ( Geddes and Harrison, 2000; Davis et al., 2003; Leucht et al., 2003; Moncrieff, 2003).”
ResultA Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018 · cited 1×
“Based on the initial finding that clozapine rapidly induces down-regulation of 5-HT2A receptors in the rat cerebral cortex ( Matsubara and Meltzer, 1989 ), Meltzer et al. (1989) examined in vitro binding potencies of a number of antipsychotic drugs to D1 ,D 2 and 5-HT2A receptors.”
BackgroundAripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Serotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Kapur, S., Zipursky, R. B., & Remington, G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 712
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Araneda, R., & Andrade, R. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90128-b · Cited by 625
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605 · cited 2×
“These effects have recently been demonstrated, as discussed later in this chapter, for their pharmacological basis (Meltzer and McGurk, 1999; Harvey and Keefe, 2001; Woodward et al., 2005 ).”
BackgroundMeltzer, H. Y. (1989) · Psychopharmacology · doi:10.1007/bf00442554 · Cited by 602
Choudhary, M. S., Craigo, S., Sibley, D. R., Roth, B. L., Monsma, F. J., Shen, Y., Uluer, A., & Meltzer, H. Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/74zp-ze10 · Cited by 592
Ichikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 494
Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Leucht, S., Pitschel-Walz, G., Engel, R. R., & Kissling, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.180 · Cited by 470
Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism
Reynolds, G. P., Zhang, Z.-J., & Zhang, X.-B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08913-4 · Cited by 412
Moghaddam, B., & Bunney, B. S. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01230.x · Cited by 402
Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396 · cited 1×
“D2 receptor occupancy of quetiapine, even at doses of 450–600 mg/day, is not more than 30% 12 h after the last dose ( Kapur et al., 2000; Gefvert et al., 2001).”
BackgroundKuroki, T., Meltzer, H. Y., & Ichikawa, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38019-x · Cited by 351
Self-citationLeysen, J. E., Janssen, P. M. F., Schotte, A., Luyten, W. H. M. L., & Megens, A. A. H. P. (1993) · Psychopharmacology · doi:10.1007/bf02245006 · Cited by 334
Yokoi, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00304-4 · Cited by 313
Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
Millan, M. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287 · cited 1×
“The 5-HT1A receptor stimulation, in addition to the 5-HT2A receptor blockade, may be the basis for clinical benefits of atypical antipsychotic drugs probably due to the functional interaction between 5-HT1A and 5-HT2A receptors (Araneda and Andrade, 1991; Wadenberg and Ahlenius, 1991; Millan, 2000 ).”
BackgroundDíaz-Mataix, L., Scorza, M. C., Bortolozzi, A., Toth, M., Celada, P., & Artigas, F. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2999-05.2005 · Cited by 285
Kapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 284
Millan, M. J., Dekeyne, A., & Gobert, A. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00078-1 · Cited by 283
Nyberg, S., Eriksson, B., Oxenstierna, G., Halldin, C., & Farde, L. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.869 · Cited by 251
Mamo, D., Graff, A., Mizrahi, R., Shammi, C. M., Romeyer, F., & Kapur, S. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06091479 · Cited by 242
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study
Newman-Tancredi, A., Gavaudan, S., Conte, C., Chaput, C., Touzard, M., Verrièle, L., Audinot, V., & Millan, M. J. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00483-x · Cited by 227
Sumiyoshi, T., Matsui, M., Nohara, S., Yamashita, I., Kurachi, M., Sumiyoshi, C., Jayathilake, K., & Meltzer, H. Y. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1722 · Cited by 207
Yamamoto, B., & Cooperman, M. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-07-04159.1994 · Cited by 203
Li, Z., Ichikawa, J., Dai, J., & Meltzer, H. Y. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.04.028 · Cited by 203
Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors.
Roth, B. L., Ciaranello, R. D., & Meltzer, H. Y. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11452-3 · Cited by 197
Ichikawa, J., Li, Z., Dai, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03570-9 · Cited by 196
Rollema, H., Lu, Y., Schmidt, A. W., Sprouse, J. S., & Zorn, S. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00850-7 · Cited by 195
Mamo, D., Kapur, S., Shammi, C. M., Papatheodorou, G., Mann, S., Therrien, F., & Remington, G. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.818 · Cited by 188
Limbic selectivity of clozapine
Pilowsky, L. S., Mulligan, R. S., Acton, P. D., Ell, P. J., Costa, D. C., & Kerwin, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63079-6 · Cited by 173
Gobert, A., & Millan, M. J. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00188-9 · Cited by 171
Xiberas, X., Martinot, J. L., Mallet, L., Artiges, E., Loc'h, C., Mazière, B., & Paillère-Martinot, M. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.503 · Cited by 171
D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study
Gefvert, O., Lundberg, T., Wieselgren, I., Bergström, M., Långström, B., Wiesel, F., & Lindström, L. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00133-4 · Cited by 158
Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertuğrul, A., & Meltzer, H. Y. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.008 · Cited by 147
Liégeois, J.-F., Ichikawa, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02620-3 · Cited by 145
Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine
KESSLER, R. M., Ansari, M. S., Riccardi, P., Li, R., Jayathilake, K., Dawant, B. M., & Meltzer, H. Y. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301108 · Cited by 135
Serotonin-6 receptor variant (C267T) and clinical response to clozapine
Yu, Y. W. ‐., Tsai, S., Lin, C., Hsu, C., Yang, K., & Hong, C. (1999) · Neuroreport · doi:10.1097/00001756-199904260-00014 · Cited by 126
Trichard, C., Paillére-Martinot, M.-L., Attar-Levy, D., Recassens, C., Monnet, F., & Martinot, J.-L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.505 · Cited by 125
Hyperactivity and Reduced Energy Cost of Physical Activity in Serotonin 5-HT2C Receptor Mutant Mice
Nonogaki, K., Abdallah, L., Goulding, E. H., Bonasera, S. J., & Tecott, L. H. (2003) · Diabetes · doi:10.2337/diabetes.52.2.315 · Cited by 123
Westerink, B. H. C., Kawahara, Y., Boer, P. D., Geels, C., Vries, J. B. D., Wikström, H., Kalkeren, A. A. V., Vliet, B. J. V., Kruse, C. G., & Long, S. K. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00935-3 · Cited by 120
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function
Jordan, S., Koprivica, V., Dunn, R. W., Tottori, K., Kikuchi, T., & Altar, C. A. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.10.025 · Cited by 117
Wadenberg, M.-L., & Ahlenius, S. (1991) · Journal of Neural Transmission · doi:10.1007/bf01244451 · Cited by 110
Meltzer, H. Y. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1088-0 · Cited by 109
In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain
Bortolozzi, A. A., Díaz-Mataix, L., Tóth, M., Celada, P., & Artigas, F. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0698-y · Cited by 106
PET Analysis Indicates Atypical Central Dopamine Receptor Occupancy in Clozapine-Treated Patients
Farde, L., & Nordstrom, A.-L. (1992) · British Journal of Psychiatry · doi:10.1192/s0007125000296888 · Cited by 106
Andersson, J. L., Nomikos, G. G., Marcus, M. M., Hertel, P., Mathé, J. M., & Svensson, T. H. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00172774 · Cited by 102
Gründer, G., Landvogt, C., Vernaleken, I., Buchholz, H., Ondracek, J., Siessmeier, T., Härtter, S., Schreckenberger, M., Stoeter, P., Hiemke, C., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300931 · Cited by 102
Knable, M. B., Heinz, A., Raedler, T. J., & Weinberger, D. R. (1997) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(97)00023-1 · Cited by 99
Talvik, M., Nordström, A.-L., Nyberg, S., Olsson, H., Halldin, C., & Farde, L. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.926 · Cited by 98
Semba, J., Watanabe, A., Kito, S., & Toru, M. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00059-f · Cited by 93
Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex
Matsubara, S., & Meltzer, H. Y. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90027-1 · Cited by 93
Youngren, K. D., Inglis, F. M., Pivirotto, P. J., Jedema, H. P., Bradberry, C. W., Goldman-Rakic, P. S., Roth, R. H., & Moghaddam, B. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00082-7 · Cited by 90
Volonté, M., Monferini, E., Cerutti, M., Fodritto, F., & Borsini, F. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010182.x · Cited by 88
East, S. Z., Burnet, P. W. J., Leslie, R. A., Roberts, J. C., & Harrison, P. J. (2002) · Synapse · doi:10.1002/syn.10097 · Cited by 87
Mukherjee, J., Christian, B. T., Narayanan, T. K., Shi, B., & Mantil, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00251-2 · Cited by 83 · cited 1×
“Mukherjee et al. (2001) report that clozapine (9.7 mg/kg, s.c.) achieves approximately 70% occupancy of D2 receptors 2–3 h after drug injection.”
BackgroundInfluentialMoncrieff, J. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.183.2.161 · Cited by 75
Travis, M. J., Busatto, G. F., Pilowsky, L. S., Mulligan, R., Acton, P. D., Gacinovic, S., Mertens, J., Terrière, D., Costa, D. C., Ell, P. J., et al. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.3.236 · Cited by 69
Li, Z., Huang, M., Prus, A. J., Dai, J., & Meltzer, H. Y. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.060 · Cited by 63
Kuroki, T., Meltzer, H. Y., & Ichikawa, J. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02516-2 · Cited by 63
Self-citationDOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release
Ichikawa, J., Dai, J., & Meltzer, H. Y. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02596-3 · Cited by 56
Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain
Frederick, J. A., & Meador‐Woodruff, J. H. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00002-x · Cited by 52
Youngren, K. D., Moghaddam, B., Bunney, B. S., & Roth, R. H. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90704-8 · Cited by 49
Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study
Chou, Y.-H., Halldin, C., & Farde, L. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1256-2 · Cited by 46
Minabe, Y., Shirayama, Y., Hashimoto, K., Routledge, C., Hagan, J. J., & Ashby, C. R. (2004) · Synapse · doi:10.1002/syn.20002 · Cited by 44
Increasing D2 affinity results in the loss of clozapineʼs atypical antipsychotic action
Kapur, S., MCCLELLAND, R. A., VanderSpek, S. C., Wadenberg, M.-L. G., Baker, G. B., Nóbrega, J. N., Zipursky, R. B., & Seeman, P. M. (2002) · Neuroreport · doi:10.1097/00001756-200205070-00019 · Cited by 41
Clozapine can induce high dopamine D 2 receptor occupancy in vivo
Suhara, T., Okauchi, T., Sudo, Y., Takano, A., Kawabe, K., Maeda, J., & Kapur, S. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0967-0 · Cited by 28
The Value of Referring to Recently Introduced Antipsychotics as “Second Generation”
Lohr, J. B., & BRAFF, D. L. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1371 · Cited by 20
Cited by
Shin, H.-W., & Chung, S. J. (2012) · Journal of Clinical Neurology · doi:10.3988/jcn.2012.8.1.15 · Cited by 354
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014) · BioMed Research International · doi:10.1155/2014/656370 · Cited by 327
“These novel antipsychotics, now referred to as second-generation antipsychotics (SGAs), have been modeled on the prototype drug clozapine [2].”
BackgroundThe role of dopamine in bipolar disorder
Cousins, D. A., Butts, K., & Young, A. H. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00760.x · Cited by 291
Brain serotonergic circuitries
Charnay, Y., & Leger, L. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.4/ycharnay · Cited by 210
Molecular and cellular analysis of human histamine receptor subtypes
Seifert, R., Strasser, A., Schneider, E. H., Neumann, D., Dove, S., & Buschauer, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.11.001 · Cited by 168
Metadata
- Authors
- KUROKI, T., NAGAO, N., & NAKAHARA, T.
- Affiliations
- Hizen Psychiatric Center (JP)
- Corresponding author
- KUROKI, T
- ORCID
- NAKAHARA, T
- Venue
- Progress in brain research
- Publisher
- Elsevier
- Published
- 2008
- Volume
- 172
- Pages
- 199-212
- ISSN
- 0079-6123 (ISSN-L)
- OpenAlex
- W1495797590
- Cited by
- 146
- References
- 85
- Citations by year
- 2025: 8 · 2024: 7 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 10 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 5 · 2014: 13 · 2013: 8 · 2012: 15
- FWCI
- 45.16
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Progress in brain research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- atypical antipsychotics, 5-HT2A receptor antagonism, dopamine D2 receptor antagonism, 5-HT1A receptor, aripiprazole, neurocognitive effects, schizophrenia, extrapyramidal symptoms, mechanism of action
- MeSH terms
- Animals, Dopamine, Humans, Receptors, Dopamine, Receptors, Serotonin, Schizophrenia, Serotonin, Serotonin Antagonists, Antipsychotic Agents, Prefrontal Cortex, Dopamine Antagonists, Protein Isoforms, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.